Teva Pharmaceuticals is trading 4.26% up now at ILA 11490.00 after positive topline Phase 2a results for TEV ’408, an investigational anti-IL-15 antibody for celiac disease.
- The study met its primary endpoint, showing statistically significant prevention of gluten-induced intestinal damage versus placebo, with favorable inflammation and symptom results and no emerging safety signals.
- Teva scheduled an investor webcast for September 2, 2026, to discuss the data.
- The catalyst appears company-specific; the healthcare sector’s 1.26% gain provided additional support.